MetaBio Registers Novel Drug Sensitivity Test Method to National Health Insurance

Published: 2005-01-28 06:57:00

Updated: 2005-01-28 06:57:00

MetaBio Co., a domestic biotechnology venture company specialized in cancer treatments and related business, recently announced that the company's drug sensitivity test method for cancer patients has been registered to the National Health Insurance (NHI) list under the non-reimbursement medical s...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK